Small molecules that inhibit the late stage of Munc13-4–dependent secretory granule exocytosis in mast cells

Received for publication, December 19, 2017, and in revised form, March 30, 2018. Published, Papers in Press, April 3, 2018. DOI 10.1074/jbc.RA117.001547

Stephen Bruinsma1, Declan J. James, Melanie Quintana Serrano2, Joseph Esquibel3, Sang Su Woo4, Elle Kielar-Grevstad, Ellen Crummy, Rehan Qureshi5, Judy A. Kowalchyk, and Thomas F. J. Martin6

From the Department of Biochemistry, University of Wisconsin, Madison Wisconsin 53706

Edited by Phyllis Hanson

Ca2+-dependent secretory granule fusion with the plasma membrane is the final step for the exocytic release of inflammatory mediators, neuropeptides, and peptide hormones. Secretory cells use a similar protein machinery at late steps in the regulated secretory pathway, employing protein isoforms from the Rab, Sec1/Munc18, Munc13/CAPS, SNARE, and synaptotagmin protein families. However, no small-molecule inhibitors of secretory granule exocytosis that target these proteins are currently available but could have clinical utility. Here we utilized a high-throughput screen of a 25,000-compound library that identified 129 small-molecule inhibitors of Ca2+-triggered secretory granule exocytosis in RBL-2H3 mast cells. These inhibitors broadly fell into six different chemical classes, and follow-up permeable cell and liposome fusion assays identified the target for one class of these inhibitors. A family of 2-amino-benzothiazoles (termed benzothiazole exocytosis inhibitors or bexins) was found to inhibit mast cell secretory granule fusion by acting on a Ca2+-dependent, C2 domain–containing priming factor, Munc13-4. Our findings further indicated that bexins interfere with Munc13-4–membrane interactions and thereby inhibit Munc13-4–dependent membrane fusion. We conclude that bexins represent a class of specific secretory pathway inhibitors with potential as therapeutic agents.

Ca2+-triggered secretory granule (SG)7 fusion with the plasma membrane is the final step in the regulated secretory pathway for protein and peptide secretion. Diverse secretory cell types employ the regulated pathway for the secretion of mucins, proteases, inflammatory mediators, biogenic amines, neuropeptides, and peptide hormones. The core machinery for Ca2+-triggered SG–plasma membrane fusion characterized in neural, neuroendocrine, and myeloid secretory cells consists of SG arginine (R)-soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins that form fusion-competent complexes with plasma membrane glutamine(Q)-SNARE proteins (1). SNARE protein complex assembly involves the concerted actions of Rab, Sec1/Munc18, and Munc13/CAPS protein family members to enable SG docking and priming (2, 3). Final Ca2+-triggered fusion steps utilize SG-localized synaptotagmins or other Ca2+ sensors (4). Constitutive secretory pathways operating in parallel utilize distinct Rab, SNARE, Sec1/Munc18, and tethering/priming factors such as the exocyst (5). Although there are many protein targets in the final steps of regulated or constitutive vesicle exocytosis, few small molecule inhibitors have been identified (see “Discussion”) (6, 7). Mechanism-selective small-molecule inhibitors would be useful for cell biological and physiological studies.

There are potential therapeutic applications for inhibitors of SG exocytosis for a number of secretory cell types, including mast cells. Mast cells store pre-formed vasoactive and pro-inflammatory mediators such as histamine, serotonin, tumor necrosis factor α (TNFα), and proteases in SGs (8, 9). Mediator release occurs by Ca2+-dependent SG exocytosis (termed degranulation) in response to allergens, pathogens, and cytokines acting at the cell surface. Mast cell mediators play roles in allergic responses, asthma, autoimmunity, and inflammation (9). Therapies for mast cell hypersecretion have targeted upstream components in signaling pathways, including FceRI IgE receptors, Syk, phosphatidylinositol 3-kinase, or Ca2+ release–activated channel (CRAC) channels (10). Alternatively, released mediators have been targeted by specific antagonists such as protease inhibitors, antihistamines, or TNFα antibodies (10). However, mechanism-specific inhibitors that directly target Ca2+-triggered degranulation have yet to be characterized (11). Such small-molecule inhibitors could provide new therapies for mast cell–linked pathways.

1 Present address: Illumina Inc., 5602 Research Park Blvd, Madison, WI 53719.
2 Present address: University of Puerto Rico, School of Medicine, San Juan, PR 00936-5067.
3 Present address: Lansing Community College, 309 N. Washington Sq., Lansing, MI 48933.
4 Present address: NINDS, National Institutes of Health, 35 Convent Dr., Bethesda, MD 20892-3719.
5 Present address: University of Chicago Graham School, 1427 E. 60th St., Chicago, IL 60637.
6 To whom correspondence should be addressed. Tel.: 608-263-2427; Fax: 608-263-4693; E-mail: tfmartin@wisc.edu.
7 The abbreviations used are: SG, secretory granule; SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor; TNF, tumor necrosis factor; ANF, atrial natriuretic factor; EGFP, enhanced GFP; bexin, benzoiazole exocytosis inhibitor; PH, pleckstrin homology; GST, glutathione S-transferase; NA, numerical aperture; GTPγS, guanosine 5′-O-(thio)triphosphate; Tf-Red, transferrin–Texas Red; Dil, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine, 4-chlorobenzenesulfonate salt; DiI, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine; TIRF, total internal reflectance fluorescence; POPs, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; DOPs, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine; brain L-α-phosphatidylinositol 4,5-bisphosphate.
Small molecule inhibitors of Munc13-4

Phenotypic assays for mast cell degranulation have been reported for high-throughput screening of chemical compound diversity libraries, and several small-molecule inhibitors have been detected (12, 13). However, it has been difficult to characterize the specific protein targets of those small molecules (14). This work utilized a series of assays to identify protein targets of inhibitors that act at final steps in Ca\(^{2+}\)-dependent SG exocytosis in mast cell-like RBL-2H3 cells. A high-throughput fluorescence-based assay was used to screen an ~25,000-compound diversity library for inhibitors of ionomycin-induced degranulation. Follow-up assays with a permeable cell assay and a SNARE-dependent liposome fusion assay discovered inhibitors that target a protein required for mast cell SG exocytosis. A family of 2-aminobenzothiazole compounds (termed bexins) was characterized as inhibitors of Munc13-4, an essential Ca\(^{2+}\)-dependent priming factor for Ca\(^{2+}\)-triggered degranulation in mast cells. Additional studies suggest that bexins interfere with membrane interactions required for Munc13-4 function in Ca\(^{2+}\)-dependent membrane fusion.

Results

High-throughput screen for small-molecule inhibitors of RBL-2H3 cell degranulation

To identify small-molecule inhibitors of degranulation, a high-throughput assay for regulated SG exocytosis in RBL-2H3 mast cells was developed. A fluorescent fusion protein, atrial natriuretic factor–enhanced GFP (ANF-EGFP) was expressed as SG cargo so that a cytoplasmic Ca\(^{2+}\) rise elicited its release by Ca\(^{2+}\)-triggered SG exocytosis. Stably expressed ANF-EGFP co-localized with the SG membrane amine transporter protein VMAT2 and the endogenous SG protease RMCP2 (Fig. 1A–F). The Ca\(^{2+}\) ionophore ionomycin stimulated the secretion of ANF-EGFP from RBL-2H3 cells (Fig. 1G). Stimulation by ionomycin bypasses upstream signaling components and cellular Ca\(^{2+}\) entry mechanisms, so the assay focused on steps in Ca\(^{2+}\)-dependent SG exocytosis downstream of Ca\(^{2+}\) entry.

The ANF-EGFP secretion assay was adapted to robotic liquid transfer in 384-well plates, and an ~25,000-compound diversity library (Life Chemicals II) was screened. Cells were pre-treated with each test compound (4 \(\mu\)M each) in DMSO (0.1% final) for 15 min before stimulation with 2 \(\mu\)M ionomycin for 15 min. Secreted ANF-EGFP in the medium was removed, and cells were solubilized in detergent to measure secreted and cell-solubilized fluorescence, respectively. Percent secretion was calculated as (medium fluorescence/(medium + cellular fluorescence)) \(\times 100\%\). 32 wells on each 384-well plate received 0.1% DMSO, and 16 of these were stimulated with ionomycin for calculating \(Z'\) values per plate.

The average percentages of ANF-EGFP secretion for unstimulated and stimulated controls were 5% and 41%, respectively. The average \(Z'\) value per plate was 0.51 (Fig. 1G), indicating a good signal for the identification of inhibitors (15). Inhibitors in the primary screen were identified as compounds that reduced secretion by more than 4 S.D. from the mean. These were retested at three concentrations (0.4, 1.3, and 4.0 \(\mu\)M), and 129 compounds were confirmed to inhibit stimulated degranulation by more than 50% at 4 \(\mu\)M. The inhibitory compounds were clustered into classes based on major ring systems as analyzed in DataWarrior using a combination of the FragFp library and International Union of Pure and Applied Chemistry nomenclature from the ChemAxon JChem Suite. Five major classes (A–E) and a diverse class (F) of inhibitors were identified (Fig. 1H).
38 of the 129 strong inhibitors were 2-aminobenzothiazoles (class A). Based on subsequent results, these were termed bexins (benzothiazole exocytosis inhibitors). Two of the strongest 2-aminobenzothiazoles, bexin-1 and -2, exhibited IC50 values of ~2.3 μM, 1.8 μM, 6.1 μM, 27.5 μM, 26.7 μM, and undetermined, respectively, as assessed by SigmaPlot.

The benzothiazole ring is extended in the same plane as the pyrazole ring in bexin-1, whereas these ring systems adopt a more compact chair-like configuration in bexin-5. In subsequent studies, bexin-5 was used as an inactive control for inhibitory bexin-1. Inhibitors in other classes (B–F) were shown to be of less interest in subsequent studies (Fig. 4).

**Cell type specificity for inhibition by bexins**

Bexin-1 inhibited secretion in RBL-2H3 cells but was much less potent in inhibiting secretion in a parallel assay employing PC12 neuroendocrine cells (Fig. 2, right column). Similarly,
bexin-2, and -3 inhibited secretion in RBL-2H3 cells but exhibited reduced inhibition in PC12 cells, even at 80 μM (Fig. 2, right column). By contrast, bexin-6, which was inactive in RBL-2H3 cells, was weakly inhibitory in PC12 cells. One explanation for different results in two cell types might be differences in membrane permeability. However, this was rendered unlikely in studies with permeable cells where drug potencies were similar to those in intact cells. Alternatively, different secretory cells might utilize different protein isoforms in regulated SG exocytosis. In this case, RBL-2H3 cells, but not PC12 cells, might express a specific protein isoform that is a target for bexins (see “Discussion”). Overall, the results shown in Fig. 2 indicate that bexins are not general inhibitors of the regulated secretory pathway but may target specific protein isoforms that are essential for regulated SG exocytosis in RBL-2H3 mast cells.

Specificity of inhibitors for mast cell exocytosis

To determine the specificity of inhibitory compounds for stimulated SG exocytosis, we utilized several orthogonal assays. The ionomycin-stimulated secretion of endogenous β-hexosaminidase was found to be strongly inhibited by bexin-1, -2, and -3 at 20 μM but not by bexin-5 or -6 (Fig. 3A). As anticipated, other compounds from the secondary screen also inhibited ionomycin-evoked β-hexosaminidase secretion, indicating
that inhibition was not selective for SG cargo. Importantly, bexin-1 also inhibited ionomycin-stimulated \( \beta \)-hexosaminidase secretion in bone marrow–derived mast cells (Fig. 3B). Bexin-1 at 10 \( \mu \)M also inhibited IgE-stimulated \( \beta \)-hexosaminidase secretion from bone marrow–derived mast cells by 78%, whereas bexin-5 did not inhibit (IgE-stimulated, 18.7% ± 7.4%; IgE plus bexin-1, 4.1% ± 4.6%, \( p < 0.05 \); IgE plus bexin-5, 31.1% ± 11.3%). Thus, inhibition by bexins was not stimulus-dependent.

In another orthogonal assay, TNF\( \alpha \) C-terminally fused with the pH-sensitive GFP variant ecliptic pHluorin was stably expressed in RBL-2H3 cells. Transmembrane TNF\( \alpha \) with its C terminus oriented toward the acidic SG lumen was nonfluorescent in resting cells because of low pH quenching. SG exocytosis stimulated by ionomycin treatment resulted in increased fluorescence at the cell surface, detected by epifluorescence microscopy (Fig. 3C). The exocytosis of TNF\( \alpha \)-pHluorin was fully inhibited by bexin-1, -2, and -3 but not by bexin-5 or -6 (Fig. 3C). As anticipated, other compound hits from the secondary screen also inhibited. Collectively, the orthogonal assays confirmed the strong inhibitory effects of bexin-1, -2, and -3 on regulated SG exocytosis independent of stimulus or SG cargo.

To determine whether other membrane trafficking pathways were affected by compounds, we monitored the uptake of fluorescent transferrin as a measure of endocytosis and endosomal trafficking. Neither bexin-1 nor bexin-5 at 20 \( \mu \)M had any effect on transferrin uptake by RBL-2H3 cells (Fig. 3D). By contrast, several other compounds from the secondary screen decreased transferrin uptake, indicating that they likely affect endocytosis. Last, compounds in serial dilutions from 2.5 to 40 \( \mu \)M exhibited little cytotoxicity, as assessed with the Alamar Blue reduction assay using 20 times longer incubations than those in secretion assays (Fig. 3E).

**Bexins act at late steps in SG exocytosis**

To further screen for inhibitors that act at late steps in Ca\(^{2+}\)-dependent secretion, we employed an assay with permeable RBL-2H3 cells. Ca\(^{2+}\)-triggered SG exocytosis can be reconstituted in washed permeable RBL-2H3 cells (17). The cells were permeabilized by a single pass through a ball homogenizer (>90% trypan blue–positive) and washed to remove soluble factors. Incubation of the permeable cells with Ca\(^{2+}\) and MgATP alone caused a modest release of ANF-EGFP (Fig. 4A), and addition of cytosol further stimulated secretion (17). The stimulatory effect of cytosol was fully replaced by the addition...
Small molecule inhibitors of Munc13-4

of 10 nm recombinant Munc13-4, as reported previously (17), or by cytosols from Munc13-4–expressing HEK293 cells but not by cytosols from sham-transfected HEK293 cells (Fig. 4A). The addition of nonhydrolyzable GTP analogs further increased Ca\(^{2+}\)-triggered ANF-EGFP release (Fig. 4A), similar to previous reports for permeabilized mast cells (18, 19). Secretion in the complete permeable cell assay was comparable with that in intact ionomycin-stimulated RBL-2H3 cells (~40–50% ANF-EGFP secreted within 10 min).

The reconstituted permeable cell assay reduced complexity and provided a direct assay for late steps in Ca\(^{2+}\)-triggered SG exocytosis (17). Anticipating that small-molecule inhibitors acting at late steps would inhibit secretion in this assay, we assembled a sublibrary of 37 compounds representative of the chemical diversity in the secondary screen for classes A–E or the strongest inhibitors in the diverse class F (Fig. 1H). Representative results of testing these compounds in triplicate assays are shown in Fig. 4, C and D (see legend). Only three compounds, bexin-1, -2, and -3, inhibited Ca\(^{2+}\)-stimulated secretion at 20 \(\mu M\) (Fig. 4C and data not shown). Bexin-1 inhibited secretion by 5 \(\mu M\), whereas the less active bexin-5 failed to inhibit at 20 \(\mu M\) (Fig. 4B) or 40 \(\mu M\) (data not shown). None of the other compounds inhibited secretion in this assay except for three compounds that were very slightly inhibitory at 40 \(\mu M\) (Fig. 4D). Thus, inhibitory bexins uniquely appeared to act at late steps in Munc13-4–dependent SG exocytosis in permeable RBL-2H3 cells.

Direct effects of bexins on the fusion machinery

Active bexins reliably inhibited Ca\(^{2+}\)-dependent SG exocytosis in intact or permeable RBL-2H3 cells (Figs. 2–4). To determine whether bexins might directly interfere with priming or fusion events that follow SG translocation and docking, we utilized a liposome fusion assay that reconstitutes aspects of priming and fusion. Donor liposomes containing R-SNAREs with DiD and acceptor liposomes containing Q-SNAREs with Dil engage in concentration-dependent lipid mixing, measured as increased FRET. Previous studies showed that SNARE-dependent lipid mixing in liposomes is stimulated by accessory proteins such as Munc13-4 + Ca\(^{2+}\) (17), Munc18-1 (20), or synaptotagmin-1 fragment C2AB + Ca\(^{2+}\) (21). We used this highly reduced system to determine whether bexins act directly on any of the essential proteins involved in SG exocytosis.

SNARE-dependent lipid mixing was accelerated by inclusion of Munc13-4 and Ca\(^{2+}\) (Fig. 5, A–C), as reported previously (17, 22). Bexin-1 and -3 fully inhibited Ca\(^{2+}\)/Munc13-4–stimulated SNARE-dependent lipid mixing without affecting the basal rates of lipid mixing in the absence of Munc13-4 or Ca\(^{2+}\) (Fig. 5, A and B). Bexin-5, which was 20-fold less active than bexin-1 in intact or permeable cell assays, had little effect on Ca\(^{2+}\) /Munc13-4-stimulated SNARE-dependent lipid mixing (Fig. 5C). Bexin-1 and -3 exerted inhibitory effects with IC\(_{50}\) values of ~5 \(\mu M\) (Fig. 5D), which approximated the IC\(_{50}\) values observed in intact and permeable cell assays. In a delayed addition study (Fig. 5E), bexin-1 was found to inhibit Ca\(^{2+}\)/Munc13-4–stimulated lipid mixing with minimal latency following its addition.

Direct effects of bexins on Munc13-4

To further assess inhibition in the SNARE-dependent lipid mixing assay, we conducted additional studies on the bexins. It was unlikely that active bexins affected SNARE protein function because the basal rates of SNARE-dependent lipid mixing were unaffected. We monitored the rates of SNARE complex formation in an independent anisotropy assay to monitor binding of the fluorescent cytoplasmic R-SNARE VAMP2 to Q-SNARE syntaxin/SNAP25–containing liposomes (Fig. 5F). Neither bexin-1 nor bexin-5 inhibited SNARE complex formation in this assay, consistent with a lack of effect of bexins on SNARE function.

We assessed the selectivity of bexins as inhibitors of Ca\(^{2+}\)/Munc13-4–dependent liposome fusion by testing other SNARE-binding regulatory proteins. Munc18-1 accelerates SNARE-dependent liposome fusion (20), but active bexin-1 and -3 as well as inactive bexin-5 failed to inhibit Munc18-1–stimulated lipid mixing (Fig. 5G). The results suggested that bexin-1 and -3 exert selectively selective inhibitory effects on Ca\(^{2+}\)/Munc13-4. Munc13-4 contains N- and C-terminal Ca\(^{2+}\)-binding C2 domains that bracket a central Munc homology domain–containing region. We also tested a protein fragment consisting of two tandem C2 domains (C2AB) from synaptotagmin-1. C2AB with Ca\(^{2+}\)-stimulated SNARE-dependent lipid mixing, as reported previously (21) (Fig. 5G). Bexin-1 and, to a lesser extent, bexin-3 inhibited C2AB-stimulated lipid mixing, whereas bexin-5 was without effect.

These findings suggest that active bexins may target the C2 domains of Munc13-4 and possibly those of other proteins. Munc13-4 associates with acidic phospholipid-containing liposomes in a Ca\(^{2+}\)-dependent manner through its C-terminal C2 domain (17, 22). Using a liposome flotation assay, we found that bexin-1, but not bexin-5, inhibited Ca\(^{2+}\)-dependent Munc13-4 binding to liposomes (Fig. 6A). Bexin-1 also inhibited the binding of C2AB to a lesser extent. As a control, bexin-1 failed to affect the binding of a PH domain to liposomes. The results suggest that bexin-1, but not bexin-5, interferes with the C2 domain–mediated association of Munc13-4 with the membrane and possibly that of other C2 domain proteins.

Munc13-4 is essential for Ca\(^{2+}\)-triggered SG-plasma membrane fusion in RBL-2H3 cells, and a fluorescent EGFP-Munc13-4 protein localizes to SGs (23). The Ca\(^{2+}\)-triggered exocytosis of SGs can be monitored in TIRF microscopy as a transfer of Munc13-4 from SGs to the plasma membrane (Fig. 6B, left panels) (23). Bexin-1 fully blocked SG exocytosis measured in this manner (Fig. 6B, right panels), whereas bexin-5 was ineffective (Fig. 6B, center panels).

SGs in Ca\(^{2+}\)-stimulated RBL-2H3 cells also undergo homotypic fusion to form vacuoles that fuse with the plasma membrane (23). We noted that the addition of bexin-1, but not bexin-5, caused dissociation of Munc13-4 from vacuole membranes, which was evident within 2.5 min of compound addition (Fig. 6C). These results were consistent with the idea that bexin-1 inhibits Ca\(^{2+}\)-, and Munc13-4–dependent membrane fusion by interfering with the association of Munc13-4 with the membrane.
**Bexins reduce SG–SG fusion and SG docking**

Bexin-1 was further tested on other aspects of SG function. As indicated above, a subset of SGs in RBL-2H3 cells engage in SG–SG fusion following ionomycin treatment to form larger multigranular vacuoles. Formation of these structures was blocked by Munc13-4 knockdown, revealing an additional activity of Munc13-4 in homotypic membrane fusion (23). In this work, we detected these compound structures with SG membrane–associated TNFα/pHluorin, which brightens in fixed cells. Although resting cells contained numerous small TNFα/pHluorin-positive SGs (Fig. 7A, control), ionomycin-treated cells contained larger (>1 μm in diameter) multigranular compound structures (Fig. 7A, ionomycin). We quantitated the extent of SG–SG fusion by counting the number of large (>6 μm²) structures per cell. Bexin-1 at 20 μM was fully effective in blocking Munc13-4–dependent SG–SG fusion (Fig. 7A, + Bexin-1). A class F compound had a similar effect. Overall, these and previous data indicate that bexin-1 targets both Munc13-4–dependent SG–plasma membrane and SG–SG fusion, which is consistent with previous findings that these Ca²⁺-dependent fusion events were blocked by knockdown of Munc13-4 (23).

The final steps in SG exocytosis involve translocation of SGs to the plasma membrane, followed by docking, priming, and fusion steps. To determine whether bexin-1 blocks translocation or the docking/priming/fusion steps, we monitored membrane-proximal SGs in ANF-EGFP–expressing cells by TIRF microscopy. Unstimulated cells contained SGs in the TIRF field that showed little movement in any direction, implying stable attachment or docking to the membrane (Fig. 7B, control). Upon stimulation with ionomycin, membrane-proximal SGs fused and disappeared from view (Fig. 7B, ionomycin). In addition, new SGs appeared in the TIRF field during stimulation, with a subset of these undergoing fusion. Newly arrived SGs comprised ~28% of all observed fusion events in stimulated cells. In a 4-min incubation with ionomycin, control cells showed a net
Small molecule inhibitors of Munc13-4

Figure 6. Bexin-1 inhibits Munc13-4 membrane binding. A, liposomes were incubated with 5 μM Munc13-4, PLC6, PH, or Syt1 C2AB + Ca²⁺ in the presence of 0.1% DMSO or 20 μM bexin-1 or -5 prior to flotation and Western blotting to detect bound proteins. Mean ± S.D. (n = 3) values are shown (*, p < 0.05; **, p = 0.01). B, RBL-2H3 cells expressing EGFP-Munc13-4 were imaged by TIRF microscopy to detect Munc13-4 on docked SGs. Cells were treated with 0.1% DMSO or 10 μM bexin-1 or -5 for 5 min prior to ionomycin stimulation for 10 min at 37 °C. EGFP-Munc13-4 fluorescence transfers to the plasma membrane during exocytosis in DMSO- or bexin-5-treated but not in bexin-1-treated cells. Scale bar = 3 μm. C, EGFP-Munc13-4 dissociates from membranes upon treatment with bexin-1 but not bexin-5. EGFP-Munc13-4 vacuole formation was stimulated in cells by treatment with ionomycin for 10 min at 37 °C, and 10 μM bexin-1 or bexin-5 was added. Vacuole fluorescence was recorded by epifluorescence during the 2.5-min incubation, and images were quantitated before and after compound addition. The arrowheads point to EGFP-Munc13-4 fluorescence on a vacuole surrounded by other smaller vacuoles. Values are mean ± S.D. (n = 3). **, p < 0.01. Scale bar = 3 μm.

~40% decrease in the number of SGs at the membrane (Fig. 7B, ione), reflecting a balance between new SG arrivals and SG fusion events. Compounds that inhibit SG fusion with the plasma membrane, but not SG translocation steps, would lead to an accumulation of SGs following stimulation. We assessed this in stimulated cells (≥16 cells per condition) by capturing live-cell images and counting the number of SGs visible in the TIRF field over the course of 4 min. Treatment with bexin-1 blocked SG fusion in this assay, resulting in SG accumulation at the membrane (Fig. 7B, + Bexin-1). By contrast, a class F compound blocked both SG fusion as well as the translocation of additional SGs to the plasma membrane (Fig. 7B, + F). Thus, consistent with previous studies, bexin-1 exerted inhibitory effects at a post-docking step of SG exocytosis.

Discussion

There are many protein targets in the final steps of regulated or constitutive vesicle exocytosis, but few small-molecule inhibitors of vesicle exocytosis have been identified (6, 7). A small-molecule inhibitor of ERK1/2 that inhibits phosphorylation of EXO70, an exocyst subunit required for constitutive exocytosis, was found to inhibit constitutive secretion (24). In addition, a small molecule that directly binds EXO70 and inhibits constitutive secretion was characterized (25). SNARE-binding polyphenols were reported to inhibit liposome fusion in vitro and SG exocytosis in RBL-2H3 cells (26, 27). Inhibitors of Rab27a–FIC1 interactions were reported to inhibit regulated azurophilic granule exocytosis in neutrophils (28). These small-molecule targets represent only a small subset of the proteins active at late steps in vesicle exocytosis.

The high-throughput assay using intact RBL-2H3 cells was poised to detect inhibitors for steps in regulated secretion beyond Ca²⁺ mobilization or entry because ionomycin mediates direct Ca²⁺ entry into the cytoplasm. The late steps of Ca²⁺-triggered SG exocytosis have been elucidated at the molecular level in mast cells (11). R-SNARE proteins on SGs form complexes with Q-SNARE proteins on the plasma membrane to mediate docking, priming, and fusion steps (1, 3). SNARE complex formation is promoted by priming factors from the Sec1/Munc18 and Munc13/CAPS protein families (2, 3) corresponding to Munc18-1-2 and Munc13-4, respectively, in RBL-2H3 cells (11, 17). Munc13-4 is expressed at high levels in RBL-2H3 cells compared with PC12 cells and may be a major target for inhibitors. Rab proteins on SGs play a role in targeting priming factors, and Rab27 binds Munc13-4 for regulated SG exocytosis in RBL-2H3 cells (29). Final Ca²⁺-triggered fusion steps are mediated by synaptotagmins in other cell types, but these have not been identified for SG exocytosis in RBL-2H3 cells (11). Any of these proteins are potential targets for inhibitor action at late steps in SG exocytosis.

We utilized a series of progressively informative assays to discover novel inhibitors of mast cell degranulation and to identify a molecular target for a set of structurally related inhibitors. Our high-throughput and secondary screen with intact RBL-2H3 cells identified 129 compounds that inhibited secretion by ≥50% inhibition at 4 μM. 38 of these contained a 2-aminothiazole scaffold, which we termed bexins. In addition, two compounds in the library that were not inhibitory in the screen served as structurally related controls (bexin-5 and -6). In assays with permeable RBL-2H3 cells or in SNARE-dependent lipid mixing, bexin-1, -2, and -3 prevailed as key inhibitors, whereas bexin-5 and -6 lacked inhibitory activity.

Benzothiazole molecules with different ring substituents exert a large variety of biological effects, including anti-cancer, anti-inflammatory, and anti-microbial activities (30). Optimized inhibitors in this class commonly harbor bulky constit-
uents at the 5- or 6- positions on the benzothiazole ring. For example, 2-aminobenzothiazoles that target phosphoinositide 3-kinase contain groups at the 6-position that help align the purine-like benzothiazole ring in the ATP-binding site of phosphoinositide 3-kinase (31). By contrast, the bexins identified in this study as active inhibitors of regulated secretion in RBL-2H3 and mast cells lack bulky substituents on the benzothiazole ring and are extended at the 2-position via amino substitutions. Extensive searches for bexin-1, -2, and -5 in the PubChem, SciFinder, and ChEMBL databases failed to identify any bioactivities reported for these molecules. By contrast, bexin-3 with its phenylsulfonylhydroquinoline substituent was found to have numerous bioactivities in PubChem. None of the bexins were pan assay interference compounds (32). Thus, this study assigns novel biological activity to bexin-1 and -2.

Permeable RBL-2H3 cells preserve late steps of regulated SG exocytosis, and studies showed that Munc13-4 is required for optimal Ca\(^{2+}\)-triggered secretion (17), indicating that Munc13-4 is a potential target for the bexins. This was explicitly tested in a liposome fusion assay that recapitulates physiological properties of Munc13-4 (17). Bexin-1 and -3 inhibited the Ca\(^{2+}\)- and Munc13-4-dependent promotion of SNARE-dependent lipid mixing. By contrast, these compounds did not affect Munc18-stimulated liposome fusion. Importantly, bexin-1 and -3 did not affect basal fusion, which indicated a lack of effect on SNARE complex formation, which was confirmed in an independent SNARE protein assembly assay. From these studies, we conclude that Munc13-4 is a direct target for inhibitory bexins.

Munc13-4 interacts with both SNARE proteins as well as with acidic phospholipid-containing membranes in a manner regulated by or mediated by the two Ca\(^{2+}\)-binding C2 domains of the protein (17, 22, 33). We found that bexin-1 inhibited the Ca\(^{2+}\)-stimulated binding of Munc13-4 to acidic phospholipid-containing liposomes. Two previous studies ascribed the Ca\(^{2+}\)-dependent membrane binding properties of Munc13-4 to its C-terminal C2-domain (17, 22), suggesting that bexin-1 interferes with a C2 domain–mediated function of Munc13-4. Moreover, we found that treatment of intact RBL-2H3 cells with bexin-1, but not bexin-5, strongly inhibited Ca\(^{2+}\)-triggered membrane fusion while concomitantly dissociating Munc13-4 from cellular membranes. This links the inhibitory effects of bexin-1 on membrane fusion to its ability to interfere with Munc13-4–membrane association. Inhibition of SG–SG fusion and SG-plasma membrane fusion with accumulation of unfused SGs by bexin-1 is similar to the impact of Munc13-4 knockdown (23), indicating that bexin-1 inhibits all of the char-

Figure 7. Effect of bexin-1 on SG–SG fusion and SG-plasma membrane fusion. A, cells expressing TNFα-pHluorin were incubated with DMSO vehicle, 20 µM bexin-1, or F2590-0733, as indicated, for 15 min and either left unstimulated (control) or stimulated with ionomycin (iono) for 15 min. Top panels, epifluorescence images of live cells, showing bright fluorescent puncta, indicating TNFα-pHluorin exocytosis. Cells were fixed, permeabilized, and stained with phalloidin-Alexa 568 and Hoechst 33342 (bottom panels). Fixation and permeabilization deacidifies SGs, allowing visualization of TNFα-pHluorin. Prior to stimulation, fluorescent puncta are small (control), whereas following stimulation (iono), larger puncta indicative of multigranular compound structures are evident. The number of large (>6 µm\(^2\)) structures per cell was quantified (mean ± S.D.; n = 3; **, p < 0.01). B, SGs docked at the plasma membrane were monitored by TIRF microscopy in RBL-2H3 cells expressing ANF-EGFP. Cells were pretreated for 15 min with vehicle (control) or 20 µM bexin-1 or 20 µM F2590-0733. Individual SGs were resolved in TIRF as individual puncta and counted. Following incubation with ionomycin for 4 min or DMSO (control), SGs were counted, and differences with the 0-min values were determined. Differences between 0- and 4-min values were not evident in the absence of stimulation, whereas a net decrease in number was found for stimulated cells. The inhibition of secretion by bexin-1 resulted in a net increase in the number of docked SGs. Values represent mean ± S.D. (n = 16–34 cells). **, p < 0.01.
New York, NY), and proteins were purified as described previously (43). Plasmids and antibodies

Experimental procedures

Plasmids and antibodies

ANF-EGFP, a kind gift from E. Levitan (University of Pittsburgh), was subcloned into lentivirus plasmids. TNFa-pHLuorin plasmids were constructed from TNFa(1–79) plasmids generously provided by M. Olszewski (Warsaw, Poland). GFP-Munc13-4 constructs were described previously (23). Plasmid constructs pTW34 to express rat syntaxin-1A with N-terminal His-tagged mouse SNAP-25B and pTW2 to express C-terminal His-tagged mouse VAMP-2 were provided by J. Rothman (Yale University, New Haven, CT) and T. Weber (Mount Sinai School of Medicine, New York, NY), and proteins were purified as described previously (44) by nickel-nitrilotriacetic acid (Qiagen) chromatography. His6-tagged human Munc13-4 protein produced in insect Sf9 cells was purified on nickel-nitrilotriacetic acid–agarose and further purified by Mono Q anion exchange chromatography (GE Healthcare). GST-C2AB (synaptotagmin-1) was prepared as described previously (45). Monoclonal antibodies to RMCP2 were obtained from Morend Scientific (Penicuik, Midlothian, Scotland). Rabbit polyclonal VMAT-2 antibody was generously provided by A. Ruoho (University of Wisconsin, Madison).

Small molecule inhibitors of Munc13-4

Small molecule inhibitors of Munc13-4 are critical for understanding the mechanism of Munc13-4 inhibition of SNARE-dependent lipid mixing. However, small molecule inhibitors of Munc13-4 are inhibited by the bexins may be the Munc13-4 C2 domain–membrane interaction will need to be clarified in future studies. A key target of Munc13-4 are inhibited by the bexins remains to be determined. Whether C2 domain proteins other than Munc13-4 are inhibited by the bexins remains to be determined.

The mechanism of inhibition by bexin-1 of Munc13-4 function will need to be clarified in future studies. A key target of bexin-1 may be the Munc13-4 C2 domain–membrane interface. C2 domains consist of eight-stranded β sandwich structures with four β-strand sheets on each side of the sandwich (39). A class of 2-arylbenzothiazoles that includes thioflavin-T has been extensively studied for binding to β sheet structures in C2 domains. The amidopyrazole ring in bexin-1, which extends from the benzothiazole ring, is lipophilic and might interact with the membrane or within the C2 domain to interfere with Ca2+-dependent Munc13-4 C2 domain membrane interactions. The inference that bexin-1 acts at a C2 domain–membrane interface will need to be tested in future studies.

Microscopy

For fluorescence microscopy, glass coverslips were coated with 0.1 mg/ml poly-d-lysine and 30 µg/ml bovine fibronectin at 37 °C (Sigma–Aldrich). Confocal images were acquired either on a Nikon C1 laser-scanning confocal microscope with a ×60 oil immersion objective with NA 1.4 or with a Nikon A1R+ confocal system using GaAsP detectors. Images were deconvolved, processed, and analyzed by NIS software (Nikon, Tokyo, Japan). TIRF images were acquired on a Nikon evanescent wave imaging system on a TE2000-U inverted microscope with an Apo TIRF ×100 NA 1.45 objective lens at 4 Hz with a CoolSNAP-ES digital monochrome charge-coupled device (CCD) camera system (Photometrics, Woburn, MA) controlled by Metamorph software (Universal Imaging, West Chester, PA). Alternatively, TIRF images were acquired on a Nikon Eclipse Ti microscope controlled by NIS Element software with image capture by an iXon Ultra EM-CCD camera through a...
Nikon APO ×100 NA 1.49 objective. Time-lapse imaging for live cells was conducted in a humidified imaging chamber maintained at 37 °C (Tokai Hit, Shizuoka-ken, Japan). Image analysis was done using Fiji/ImageJ (42) or NIS Element software.

**Cell secretion assays**

Live-cell secretion assays with ANF-EGFP—expressing RBL-2H3 and PC12 cells were performed in Tyrode buffer (130 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 20 mM HEPES, 5.6 mM glucose, and 0.5 mg/ml BSA (pH 7.4)). Cell monolayers were washed, and compounds were added 15 min prior to the addition of buffer (control) or 2 μM ionomycin for 15 min at 37 °C. Fluorescence at 488 nm excitation of ANF-EGFP in buffer overlying cells was determined after low-speed centrifugation to remove detached cells, and attached cells were solubilized in 1% Triton X-100 for calculating percent secretion. The secretion of β-hexosaminidase by RBL-2H3 cells was determined in a similar format by monitoring enzymatic activity in supernatants and solubilized cells using the chromogenic substrate 4-nitrophenyl N-acetyl-β-D-glucosaminide (pNAG) as described previously (23). For antigen stimulation, cells were primed with 200 ng/ml anti-2,4-dinitrophenol monoclonal IgE in growth medium overnight and subsequently washed with Tyrode buffer and incubated with 50 ng/ml 2,4-dinitrophenol–human serum albumin in Tyrode buffer containing 2 mM CaCl₂ for 20 min.

**High-throughput screening**

Automated liquid handling and drug library screening were conducted at the University of Wisconsin Small Molecule Screening Facility. Drugs were applied by pin transfer, and automated liquid transfer was performed by Biomek FX. The compound library (LC II) from Life Chemicals was provided as 4 mm stocks in DMSO by the University of Wisconsin Small Molecule Screening Facility. Compounds annotated in this study are given as the external identifier given by Life Chemicals that are searchable in PubChem.

**Permeable cell secretion assays**

Permeable RBL-2H3 and PC12 cell secretion assays were conducted with cells permeabilized by passage through an appropriately fitted ball homogenizer (48). A stable clone of RBL-2H3 rat mast cells expressing ANF-EGFP was generated by lentiviral transduction. Targeting of ANF-EGFP to secretory granules and cosecretion with the endogenous granule marker β-hexosaminidase were confirmed. Permeable RBL-2H3 secretion assays were conducted at 30 °C in buffers containing 0.05 M HEPES, 0.12 M potassium glutamate, 0.002 M EGTA, and 0.1% BSA (pH 7.2) adjusted to 3 μM free Ca²⁺ and containing 2 mM MgATP and 10 μM GTPγS. The cytosol used in the RBL-2H3 cell assays was prepared from COS-1 cells, either WT (sham) or expressing Munc13-4, by homogenization in ice-cold 0.02 M HEPES (pH 7.5), 0.002 M EGTA, 0.001 M EDTA, 0.001 M DTT, 0.0001 M phenylmethylsulfonyl fluoride, and 0.5 μg/ml leupeptin using multiple passes in a ball homogenizer, followed by centrifugation at 30,000 × g for 30 min and 100,000 × g for 90 min. In some assays, purified Munc13-4 was used for comparison. After incubation, RBL-2H3 cells were centrifuged at 650 × g, and the supernatant and 1% Triton X-100–solubilized pellet fractions were assessed for fluorescence in a plate reader (Infinite F500, Tecan Group Ltd.) to determine the percentage of ANF-EGFP secreted.

**Liposome fusion assays, liposome binding, and SNARE complex formation**

Lipid-mixing fusion assays were conducted as described previously (17, 23, 49). Lipid mixing was reported as FRET between DiI-containing VAMP-2 liposomes and DiD-containing syntaxin-1A/SNAP-25 liposomes. The standard assay used 0.45 mM of acceptor and 0.225 mM of donor liposomes in a total volume of 75 μl of reconstitution buffer without glycerol supplemented with 0.1 mM EGTA. Munc13-4 protein was added at the concentrations indicated in the figure legends. CaCl₂ was added to achieve the free Ca²⁺ indicated in the figures. Control reactions were prepared for all conditions by substituting syntaxin-1A/SNAP-25 acceptor liposomes with protein-free liposomes to detect non-SNARE-mediated lipid mixing. Reactions were assembled on ice and mixed before addition to 96-well FluoroNunc plates. Lipid mixing was observed as an increase in FRET from DiI to DiD labels by measuring DiD fluorescence at 700 ± 5 nm during DiI excitation at 514 ± 5 nm every 90 s over 2 h at 35 °C using the SPECTraMax GEMINI-XS spectrophotometer (Molecular Devices, Sunnyvale, CA). Results are expressed as the ratio of fluorescence at time x/minimum fluorescence measured over 2 h. SNARE complex formation was determined by anisotropy utilizing syntaxin-1A/SNAP25 acceptor liposomes incubated with a cytoplasmic domain of VAMP2 labeled at residue 28 with Alexa Fluor 488, similar as described previously (50).

Liposomes were generated by resuspending a nitrogen gas–dried lipid film containing 1.5 μmol of POPC/DOPS/PI(4,5)P₂ in an 87:12:1 mole ratio in 500 μl of elution buffer (25 mM HEPES-KOH (pH 7.4), 100 mM KCl, 50 mM imidazole-OAc (pH 7.4), and 1.0% β-octylglucoside) for 30 min, diluted 2-fold with reconstitution buffer (25 mM HEPES (pH 7.4), 100 mM KCl, 10% glycerol, and 1 mM DTT) by dropwise addition, and dialysis overnight against reconstitution buffer containing Bio-Beads (Bio-Rad). Lipid mixtures were spiked with 2 μl of [³H]1,2-dipalmitoyl phosphatidylcholine (~2 × 10⁵ cpm/nmol, DuPont) to assess lipid recoveries and to standardize co-flotation assay reactions. The liposomes were purified by buoyant density centrifugation on an Accudenz step gradient (3 ml at 40%, 2 ml at 30%, and 0.5 ml at 0% in reconstitution buffer) at 45,000 rpm for 4 h in an SW50.1 rotor (Beckman Coulter). Liposome co-flotation assays were performed as described previously (44) with modifications. Liposomes were incubated with 5 μM Munc13-4, GST–Syt1C2AB, or PLCδ₅·PH–GFP and, where indicated, plus 400 μM calcium for 30 min at room temperature in 75 μl of reconstitution buffer. Compounds were added to reactions after protein for a final concentration of 20 μM and 0.6% v/v DMSO. In reactions without compounds, DMSO was added to yield a final concentration of 0.6% v/v. 75 μl of 80% Accudenz was added to the binding reaction to yield a final concentration of 40% Accudenz. 30% Accudenz and reconstitution buffers were layered on top and centrifuged for
Small molecule inhibitors of Munc13-4

4 h in an SW50.1 rotor at 45,000 rpm. Accudenz gradient layers were supplemented with calcium and compounds to provide concentrations equivalent to those in the binding reactions. Either the floated fraction or all fractions were collected, run on SDS-PAGE, and analyzed by Western blotting or SYPRO Ruby staining. ImageJ/Fiji software (National Institutes of Health) was used to quantify protein bands. Constructs encoding PLCδ, PH-GFP were generously provided by T. Balla (National Institutes of Health) and GST-Syt1C2AB by E. Chapman (University of Wisconsin, Madison, WI) for protein production in Escherichia coli as described previously (51, 52).

Author contributions—S. B. and T. F. J. M. conceptualization; S. B., D. J. J., M. Q. S., J. E., S. S. W., E. K.-G., and E. C. methodology; S. B., D. J. J., M. Q. S., J. E., S. S. W., E. K.-G., and E. C. validation; S. B., D. J. J., M. Q. S., J. E., S. S. W., E. K.-G., and E. C. investigation; S. B., D. J. J., M. Q. S., J. E., S. S. W., E. K.-G., and E. C. writing—original draft; S. B., D. J. J., and T. F. J. M. writing—review and editing.

Acknowledgments—Authors acknowledge the University of Wisconsin Small Molecule Screening facility for access to the LCII compound library and robotics and the University of Wisconsin Biochemistry Optical Core facility for microscopy. We thank S. Rice for extensive database searches and E. Lingeman for studies on endocytosis.

References

1. Milovanovic, D., and Jahn, R. (2015) Organization and dynamics of SNARE proteins in the presynaptic membrane. Front. Physiol. 6, 89 CrossRef Medline

2. James, D. J., and Martin, T. F. (2013) CAPS and Munc13: CATCHRs that SNARE vesicles. Front. Endocrinol. (Lausanne) 4, 187 CrossRef Medline

3. Rizo, J., and Xu, J. (2015) The synaptic vesicle release machinery. Annu. Rev. Biophys. 44, 339–367. CrossRef Medline

4. Pinheiro, P. S., Housy, S., and Sorensen, J. B. (2016) C2-domain containing calcium sensors in neuroendocrine secretion. J. Neurochem. 139, 943–958 CrossRef Medline

5. Hong, W., and Lev, S. (2014) Tethering the assembly of SNARE complexes. Trends Cell Biol. 24, 35–43. CrossRef Medline

6. Mishev, K., Dejonghe, W., and Russinova, E. (2013) Small molecules for dissecting endomembrane trafficking: a cross-systems view. Trends Cell Biol. 23, 35–43. CrossRef Medline

7. Ivanov, A. I. (2014) Pharmacological inhibitors of exocytosis and endocytosis: novel bullets for old targets. Methods Mol. Biol. 1174, 3–18. CrossRef Medline

8. Moon, T. C., Befus, A. D., and Kulka, M. (2014) Mast cell mediators: their differential release and the secretory pathways involved. Front. Immunol. 5, 569 Medline

9. Wernersson, S., and Pejler, G. (2014) Mast cell secretory granules: armed for battle. Nat. Rev. Immunol. 14, 478–494. CrossRef Medline

10. Harvima, I. T., Levi-Schaffer, F., Draber, P., Friedman, S., Polakovicova, I., Gibbs, B. F., Blank, U., Nilsson, G., and Maurer, M. (2014) Molecular targets on mast cells and basophils for novel therapies. J. Allergy Clin. Immunol. 134, 530–544. CrossRef Medline

11. Blank, U., Madera-Salcedo, I. K., Danelli, L., Claver, J., Tiwari, N., Sánchez-Miranda, E., Vázquez-Victorio, G., Ramírez-Valadez, K. A., Macías-Silva, M., and González-Espinoza, C. (2014) Vesicular trafficking and signaling for cytokine and chemokine secretion in mast cells. Front. Immunol. 5, 453 Medline

12. Matsuda, H., Nakamura, S., and Yoshikawa, M. (2016) Degranulation inhibitors from medicinal plants in antigen-stimulated rat basophilic leukaemia (RBL-2H3) cells. Chem. Pharm. Bull. 64, 96–103. CrossRef Medline

13. McShane, M. P., Friedrichson, T., Giner, A., Meyenhofer, F., Baracchini, R., Bickle, M., and Zerial, M. (2015) A combination of screening and computational approaches for the identification of novel compounds that decrease mast cell degranulation. J. Biol. Chem. Screen 20, 720–728. CrossRef Medline

14. Rossi, A. B., Herlaar, E., Braselmann, S., Huynh, S., Taylor, V., Frances, R., Issakani, S. D., Argade, A., Singh, R., Payan, D. G., and Masuda, E. S. (2006) Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J. Allergy Clin. Immunol. 118, 749–755. CrossRef Medline

15. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67–73. CrossRef Medline

16. Schüttelkopf, A. W., and van Aalten, D. M. (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355–1363. CrossRef Medline

17. Boswell, K. L., James, D. J., Esquibel, J. M., Bruinsma, S., Shirakawa, R., Horiuchi, H., and Martin, T. F. (2012) Munc13-4 reconstitutes calcium-dependent SNARE-mediated membrane fusion. J. Cell Biol. 197, 301–312. CrossRef Medline

18. Howell, T. W., Cockcroft, S., and Gomperts, B. D. (1987) Essential synergy between Ca2+ and guanine nucleotides in exocytotic secretion from permeabilized rat mast cells. J. Cell Biol. 105, 191–197. CrossRef Medline

19. Shirakawa, R., Higashi, T., Tabuchi, A., Yoshioka, A., Nishioka, H., Fukuda, M., Kita, T., and Horiuchi, H. (2004) Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. J. Biol. Chem. 279, 10730–10737. CrossRef Medline

20. Shen, J., Tareste, D. C., Paument, F., Rothman, J. E., and Melia, T. J. (2007) Selective activation of cognate SNAREpins by Sec1/Munc18 proteins. Cell 128, 183–195. CrossRef Medline

21. Tucker, W. C., Weber, T., and Chapman, E. R. (2004) Reconstitution of Ca2+-regulated membrane fusion by synaptotagmin and SNAREs. Science 304, 435–438. CrossRef Medline

22. Chica, M. C., Ren, Q., Richards, D., Hellman, L. M., Zhang, J., Fried, M. G., and Whiteheart, S. W. (2016) Role of Munc13-4 as a Ca2+-dependent tether during platelet secretion. Biochem. J. 473, 627–639. CrossRef Medline

23. Woo, S. S., James, D. J., and Martin, T. F. (2017) Munc13-4 functions as a Ca2+ sensor for homotypic secretory granule fusion to generate endosomal exocytic vacuoles. Mol. Biol. Cell 28, 792–808. CrossRef Medline

24. Ren, J., and Guo, W. (2012) ERK1/2 regulate exocytosis through direct phosphorylation of the exocyst component Exo70. Dev. Cell 22, 967–978. CrossRef Medline

25. Zhang, C., Brown, M. Q., van de Ven, W., Zhang, Z. M., Wu, B., Young, M. C., Synek, L., Borchardt, D., Harrison, R., Pan, S., Luo, N., Huang, Y. M., Ghang, Y. J., Ung, N., Li, R., et al. (2016) Endosin2 targets conserved exocyst complex subunit EXO70 to inhibit exocytosis. Proc. Natl. Acad. Sci. U.S.A. 113, E41–50. CrossRef Medline

26. Yang, Y., Oh, J. M., Heo, P., Shin, J. Y., Kong, B., Shin, J., Lee, J. C., Oh, J. S., Park, K. W., Lee, C. H., Shin, Y. K., and Kweon, D. H. (2013) Polyphenols differentially inhibit degranulation of distinct subsets of vesicles in mast cells by specific interaction with granule-type-dependent SNARE complexes. Biochem. J. 450, 537–546. CrossRef Medline

27. Yang, Y., Shin, J. Y., Oh, J. M., Jung, C. H., Hwang, Y., Kim, S., Kim, J. S., Yoon, K. J., Ryu, J. Y., Shin, J., Hwang, J. S., Yoon, T. Y., Shin, Y. K., and Kweon, D. H. (2010) Dissection of SNARE-driven membrane fusion and neuroexocytosis by wedging small hydrophobic molecules into the SNARE zipper. Proc. Natl. Acad. Sci. U.S.A. 107, 22145–22150. CrossRef Medline

28. Johnson, J. L., Ramadass, M., He, J., Brown, S. J., Zhang, J., Abgarian, L., Biris, N., Gavathiotis, E., Rosen, H., and Catz, S. D. (2016) Identification of neutralophil exocytosis inhibitors (Nexinhibs), small molecule inhibitors of neutralophil exocytosis and inflammation: druggability of the small GTPase Rab27a. J. Biol. Chem. 291, 25965–25982. CrossRef Medline

29. Catz, S. D. (2013) Regulation of vesicular trafficking and leukocyte function by Rab27 GTPases and their effectors. J. Leukocyte Biol. 94, 613–622. CrossRef Medline

30. Keri, R. S., Patil, M. R., Patil, S. A., and Budagumpi, S. (2015) A comprehensive review in current developments of benzothiazole-based mole-
cules in medicinal chemistry. *Eur. J. Med. Chem.* **89**, 207–251 CrossRef Medline
31. D’Angelo, N. D., Kim, T. S., Andrews, K., Booker, S. K., Caenepeel, S., Chen, K., D’Amico, D., Freeman, D., Jiang, J., Liu, L., McCarter, J. D., San Miguel, T., Mullady, E. L., Schrag, M., Subramanian, R., et al. (2011) Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors. *J. Med. Chem.* **54**, 1789–1813 CrossRef Medline
32. Baell, J. B., and Holloway, G. A. (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J. Med. Chem.* **53**, 2719–2740 CrossRef Medline
33. He, J., Johnson, J. L., Monfregola, J., Ramadass, M., Pensonjamasp, K., Napolitano, G., Zhang, J., and Catz, S. D. (2016) Munc13-4 interacts with syntaxin 7 and regulates late endosomal maturation, endosomal signaling, and TLR9-initiated cellular responses. *Mol. Biol. Cell* **27**, 572–587 CrossRef Medline
34. Vennekate, W., Schröder, S., Lin, C. C., van den Bogaart, G., Grunwald, M., Jahn, R., and Walla, P. J. (2012) Cis- and trans-membrane interactions of synaptotagmin I. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 11037–11042 CrossRef Medline
35. Lynch, K. L., and Martin, T. F. (2007) Synaptotagmins I and IX function redundantly in regulated exocytosis but not endocytosis in PC12 cells. *J. Cell Sci.* **120**, 617–627 CrossRef Medline
36. Sagi-Eisenberg, R. (2007) The mast cell: where endocytosis and regulated exocytosis meet. *Immunol. Rev.* **217**, 292–303 CrossRef Medline
37. Knight, Z. A., and Shokat, K. M. (2008) Features of selective kinase inhibitors. *Chem. Biol.* **15**, 621–637 CrossRef Medline
38. Pelish, H. E., Peterson, J. R., Salvarezza, S. B., Rodriguez-Boulan, E., Chen, J. L., Stammes, M., Macia, E., Feng, Y., Shair, M. D., and Kirchhausen, T. (2006) Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation *in vitro*. *Nat. Chem. Biol.* **2**, 39–46 CrossRef Medline
39. Rizo, J., and Söllner, T. H. (1998) C2-domains, structure and function of a universal Ca2⁺-binding domain. *J. Biol. Chem.* **273**, 15879–15882 CrossRef Medline
40. Cukalevski, R., Boland, B., Frohm, B., Thulin, E., Walsh, D., and Linse, S. (2012) Role of aromatic side chains in amyloid β-protein aggregation. *ACS Chem. Neurosci.* **3**, 1008–1016 CrossRef Medline
41. Wang, C., Yang, A., Li, X., Li, D., Zhang, M., Du, H., Li, C., Guo, Y., Mao, X., Dong, M., Beisenbacher, F., Yang, Y., and Wang, C. (2012) Observation of molecular inhibition and binding structures of amyloid peptides. *Nano- scale* **4**, 1895–1909 CrossRef Medline
42. Biancalana, M., and Koide, S. (2010) Molecular mechanism of Thioflavin-T binding to amyloid fibrils. *Biochim. Biophys. Acta* **1804**, 1405–1412 CrossRef Medline
43. Noël, S., Cadet, S., Gras, E., and Hureau, C. (2013) The benzazole scaffold: a SWAT to combat Alzheimer’s disease. *Chem. Soc. Rev.* **42**, 7747–7762 CrossRef Medline
44. Weber, T., Zemelman, B. V., McNew, J. A., Westermann, B., Gmachl, M., Parlati, F., Söllner, T. H., and Rothman, J. E. (1998) SNAREpins: minimal machinery for membrane fusion. *Cell* **92**, 759–772 CrossRef Medline
45. Gerona, R. R., Larsen, E. C., Kowalchyk, J. A., and Martin, T. F. (2000) The C terminus of SNAP25 is essential for Ca2⁺-dependent binding of synaptotagmin to SNARE complexes. *J. Biol. Chem.* **275**, 6328–6336 CrossRef Medline
46. Vukman, K. V., Metz, M., Maurer, M., and O’Neill, S. M. (2014) Isolation and culture of bone marrow-derived mast cells. *Bio-protocol* **4**, e1053
47. Klenchin, V. A., Kowalchyk, J. A., and Martin, T. F. (1998) Large dense-cored vesicle exocytosis in PC12 cells. *Methods* **16**, 204–208 CrossRef Medline
48. Martin, T. F. (1989) Cell cracking: permeabilizing cells to macromolecular probes. *Methods Enzymol.* **168**, 225–233 CrossRef Medline
49. James, D. J., Kowalchyk, J., Daily, N., Petrie, M., and Martin, T. F. (2009) CAPS drives trans-SNARE complex formation and membrane fusion through syntaxin interactions. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 17308–17313 CrossRef Medline
50. Pobbari, A. V., Stein, A., and Fasshauer, D. (2006) N- to C-terminal SNARE complex assembly promotes rapid membrane fusion. *Science* **313**, 673–676 CrossRef Medline
51. James, D. J., Khodthong, C., Kowalchyk, J. A., and Martin, T. F. (2008) Phosphatidylinositol 4,5-bisphosphate regulates SNARE-dependent membrane fusion. *J. Cell Biol.* **182**, 355–366 CrossRef Medline
52. Lynch, K. L., Gerona, R. R., Larsen, E. C., Marcia, R. F., Mitchell, J. C., and Martin, T. F. (2007) Synaptotagmin C2A loop 2 mediates Ca²⁺-dependent SNARE interactions essential for Ca²⁺-triggered vesicle exocytosis. *Mol. Biol. Cell* **18**, 4957–4968 CrossRef Medline
53. van den Hoff, M. J., Moorman, A. F., and Lamers, W. H. (1992) Electro-permeabilization of neural cell cultures and for their exclusion in bioassays. *J. Med. Chem.* **35**, 1789–1804, 225–233 CrossRef Medline
54. Luchillow, T., Koziel, M., Jahn, R., and Walla, P. J. (2006) Synaptotagmin to SNARE complexes. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 16883–16888 CrossRef Medline
55. Klenchin, V. A., Kowalchyk, J. A., and Martin, T. F. (1998) Large dense-cored vesicle exocytosis in PC12 cells. *Methods* **16**, 204–208 CrossRef Medline
56. Martin, T. F. (1989) Cell cracking: permeabilizing cells to macromolecular probes. *Methods Enzymol.* **168**, 225–233 CrossRef Medline
57. James, D. J., Kowalchyk, J., Daily, N., Petrie, M., and Martin, T. F. (2009) CAPS drives trans-SNARE complex formation and membrane fusion through syntaxin interactions. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 17308–17313 CrossRef Medline
58. Pobbari, A. V., Stein, A., and Fasshauer, D. (2006) N- to C-terminal SNARE complex assembly promotes rapid membrane fusion. *Science* **313**, 673–676 CrossRef Medline
59. James, D. J., Khodthong, C., Kowalchyk, J. A., and Martin, T. F. (2008) Phosphatidylinositol 4,5-bisphosphate regulates SNARE-dependent membrane fusion. *J. Cell Biol.* **182**, 355–366 CrossRef Medline
60. Lynch, K. L., Gerona, R. R., Larsen, E. C., Marcia, R. F., Mitchell, J. C., and Martin, T. F. (2007) Synaptotagmin C2A loop 2 mediates Ca²⁺-dependent SNARE interactions essential for Ca²⁺-triggered vesicle exocytosis. *Mol. Biol. Cell* **18**, 4957–4968 CrossRef Medline
61. van den Hoff, M. J., Moorman, A. F., and Lamers, W. H. (1992) Electro-permeabilization of neural cell cultures and for their exclusion in bioassays. *J. Med. Chem.* **35**, 1789–1804, 225–233 CrossRef Medline